Boston Scientific to Acquire Valencia Technologies to Expand Leadership in Urology with First FDA-Approved Implantable Tibial Nerve Stimulator eCoin

Jan 13, 2026 17:43 CST Updated 17:43

Valencia Technologies

Developer of Implantable Neurostimulation Devices

Home of Medical Devices

Pioneer in Medical Device Media Coverage

Sharing Professional Medical Device Knowledge

Source: Medical Device Business Review

On January 12, 2026, Boston Scientific announced that it had reached a final agreement to acquire Valencia Technologies, an innovative company in the field of implantable tibial nerve stimulation (ITNS), at an undisclosed price.

This acquisition marks another major strategic move by Boston Scientific in the urology field, following its $3.7 billion acquisition of Axonics in 2024.

Core Product eCoin:

Redefining Urinary Incontinence Treatment

Valencia's core product, eCoin, isThe World's FirstFDA-Approved Implantable Tibial Nerve Stimulator: Its Revolutionary Design Breaks Through the Limitations of Traditional Treatments:

Miniaturized Design:Coin-sized (25 mm in diameter), requires only outpatient implantation under local anesthesia, with a discreet appearance post-implantation
Intelligent Leadless Technology:Built-in battery and chip for continuous, stable delivery of tibial nerve stimulation via a dome-shaped stimulation field, avoiding lead-related complications associated with traditional sacral nerve stimulators.
Clinical Validation:Key Trial Shows ≥50% Reduction in Urgency Urinary Incontinence Episodes in 68% of Patients, with Long-Term Safety Confirmed
Differentiated Advantages:Compared with sacral nerve stimulators, the eCoin system features minimal surgical trauma, a low complication rate, and high patient acceptance, having accumulated extensive clinical experience over many years since its market launch.

eCoin System

Market Landscape and Strategic Value

Approximately 30 million Americans aged 40 and olderUpperOveractive Bladder (OAB）Patients have long faced therapeutic dilemmas. Although traditional sacral nerve stimulation is effective, few patients are willing to undergo this therapy due to its surgical complexity, high invasiveness, and elevated risk of complications.

The emergence of eCoin has pioneered a new, safer, and more convenient track for ITNS therapy, with its clinical advantages already validated. Through this acquisition, Boston Scientific has achieved the following strategic breakthroughs:

Rapidly enter the fast-growing ITNS market, complementing the existing Axonics product portfolio
Developing a full-course disease management solution, covering the entire treatment spectrum from conservative therapy to neuromodulation
Seize First-Mover Advantage to Counter Competitive Pressure from Medtronic and Other Rivals

Financial Impact and Future Outlook

The transaction is expected to be completed in the first half of 2026, with a neutral impact on adjusted earnings per share for the year; dilution under GAAP is controllable.

Meghan Scanlon, President of Boston Scientific’s Urology business, stated, “The addition of eCoin will drive our expansion into the high-growth ITNS sector. Its technology creates synergies with our existing pelvic health portfolio, ultimately enabling us to provide patients with more comprehensive, full-course treatment solutions.”

Overactive bladder (OAB) profoundly impacts patients’ quality of life, affecting multiple dimensions including mental health, sleep, and work productivity. While conventional treatments are limited by suboptimal efficacy or excessive invasiveness, neuromodulation therapy is emerging as a mainstream approach. This acquisition will further strengthen Boston Scientific’s leadership position in urology.

END

Tech Giant to Cut 22,000 Jobs, Affecting Medical Division

"The First Stock of Large Medical Imaging Models" Submits Listing Application to the Hong Kong Stock Exchange

FDA Loosens Regulations on Wearable Health Devices

Midea’s Executive President Takes Helm at Carestream Health

Stryker, a Business Acquired

GE Healthcare Responds to Hostile Takeover

“The Only One in China,” Launches IPO

Domestic Imaging Leader Drives “World’s No. 2” to List on the STAR Market

Johnson & Johnson Re-enters the Surgical Robotics Race

Stryker: Multiple Major Personnel Changes

ShangBusiness Cooperation Email: qxzj@landianyiliao.com